In continuation of my update on carboplatin
Researchers from IU Medical Sciences Program-Bloomington and Indiana University Melvin, have found that, an experimental two-drug combination (decitabine & carboplatin) for treating late-stage ovarian cancer
continues to produce strong results, leading its Indiana University
researchers to actively pursue the next step, conducting a larger
clinical trial to test the therapy and to see how it compares with
existing treatments for ovarian cancer.
The researchers have been investigating the addition of decitabine,
which is marketed as Dacogen in the United States, because they suspect
it reactivates tumor suppression genes that are turned off in ovarian cancer cells and improves cells' susceptibility to anti-cancer drugs like carboplatin.
More..."The science associated with the trial is novel and exciting and could have impact in the future," she said.....
1 comment:
Thanks for sharing the idea there would be some apprehensions from segment but i am up for it.
Post a Comment